Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study.
Rahbar K, Essler M, Pabst KM, Eiber M, Fougère C, Prasad V, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Fendler WP, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. Among authors: verholen f. J Nucl Med. 2023 Apr;64(4):574-578. doi: 10.2967/jnumed.122.264456. Epub 2022 Oct 27. J Nucl Med. 2023. PMID: 36302656 Free PMC article.
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T, MacLennan SJ, Axelsson SE, Gandaglia G, Willemse PP, Mastris K, Ransohoff JB, Devecseri Z, Abbott T, De Meulder B, Bjartell A, Asiimwe A, N'Dow J; PIONEER Consortium. Omar MI, et al. Nat Rev Urol. 2023 Aug;20(8):494-501. doi: 10.1038/s41585-023-00748-9. Epub 2023 Apr 3. Nat Rev Urol. 2023. PMID: 37012441 Review.
Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
Russell B, Beyer K, Lawlor A, Roobol MJ, Venderbos LDF, Remmers S, Briers E, MacLennan SJ, MacLennan S, Omar MI, Van Hemelrijck M; PIONEER Consortium. Russell B, et al. Eur Urol Open Sci. 2023 Dec 19;59:27-29. doi: 10.1016/j.euros.2023.11.004. eCollection 2024 Jan. Eur Urol Open Sci. 2023. PMID: 38298764 Free PMC article.
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.
O'Sullivan JM, McKay RR, Rahbar K, Fizazi K, George DJ, Tombal B, Schmall A, Sandström P, Verholen F, Shore N. O'Sullivan JM, et al. Among authors: verholen f. Front Med (Lausanne). 2022 Dec 22;9:fmed-09-1070392. doi: 10.3389/fmed.2022.1070392. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619649 Free PMC article. Review.
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.
Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, Sternberg CN, Saad F, Sade JP, Bellmunt J, Smith MR, Chandrawansa K, Sandström P, Verholen F, Tombal B. Higano CS, et al. Among authors: verholen f. EClinicalMedicine. 2023 May 18;60:101993. doi: 10.1016/j.eclinm.2023.101993. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37251627 Free PMC article.
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study).
Rahbar K, Essler M, Eiber M, la Fougère C, Prasad V, Fendler WP, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Pabst KM, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. Among authors: verholen f. J Nucl Med. 2023 Dec 1;64(12):1925-1931. doi: 10.2967/jnumed.123.266125. J Nucl Med. 2023. PMID: 37827838 Free PMC article.
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, Tomaszewski JJ, Saad F, Miller K, Meltzer J, Sandström P, Verholen F, Tombal B, Sartor O. Higano CS, et al. Among authors: verholen f. Cancer. 2024 Jun 1;130(11):1930-1939. doi: 10.1002/cncr.35221. Epub 2024 Feb 10. Cancer. 2024. PMID: 38340349
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Hussain M, et al. Among authors: verholen f. J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16. J Clin Oncol. 2023. PMID: 36795843 Clinical Trial.
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F. Fizazi K, et al. Among authors: verholen f. Eur J Cancer. 2023 Oct;192:113258. doi: 10.1016/j.ejca.2023.113258. Epub 2023 Jul 27. Eur J Cancer. 2023. PMID: 37660438 Free article. Clinical Trial.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR. Saad F, et al. Among authors: verholen f. Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.03.036. Online ahead of print. Eur Urol. 2024. PMID: 38644146 Free article.
27 results